Bay­er to pull fol­lic­u­lar lym­phoma drug Aliqopa from US mar­ket in an­oth­er blow to PI3K in­hibitor space

Bay­er said it will vol­un­tar­i­ly with­draw its fol­lic­u­lar lym­phoma drug Aliqopa from the US af­ter a con­fir­ma­to­ry tri­al dis­ap­point­ment, mark­ing the third PI3K in­hibitor to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER